Description

Cytosar has been used experimentally in a variety of neoplastic diseases. In general, few patients with solid tumors have benefited. Children with non-Hodgkin’s lymphoma have benefited from a combination drug program (LSA2L2) that includes Cytosar. Cytosar in a high-dose regimen with or without additional cancer chemotherapeutic agents, has been shown to be effective in the treatment of poor-risk leukemia, refractory leukemia and relapsed acute leukemia. Cytosar alone or in combination with other drugs (methotrexate, hydrocortisone sodium succinate) is used intrathecally for prophylaxis or treatment of meningeal leukemia.